China, Nanjing-based company Triastek, a pioneer in 3D printing for the pharmaceutical industry, successfully raised an impressive USD 20.4M in a Pre-C funding round. The investment was led by Guoxin Investment, with significant participation from Goldmine Multi-Family Office and existing investor Mr. Xiaodong Zheng, President of Shanghai Tofflon Science and Technology Co. This substantial funding injection will propel Triastek in accelerating the innovation of its pharmaceutical solutions, particularly in drug development and manufacturing. Triastek, founded by Dr. Senping Cheng, utilizes its proprietary Melt Extrusion Deposition (MED®) 3D printing process, coupled with digital formulation development methods, to design and develop medications with complex drug delivery and programmed release capabilities. The company is actively exploring new technological processes, including Semi-Solid Extrusion, Micro-Injection Molding, and Micro-Droplet Jetting, to further enhance their pharmaceutical delivery solutions. Triastek's established strategic partnerships with industry giants like Eli Lilly, Merck KGaA, Boehringer Ingelheim, Siemens, and Sperogenix demonstrate its potential to revolutionize drug development and delivery in the pharmaceutical landscape.